Drug intelligence / Profile preview

EuPCV15

Development stage: Phase 1
Lead developer: EuBiologics
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

EuPCV15 is a 15-valent pneumococcal conjugate vaccine developed by EuBiologics Co.,Ltd. It is designed to protect against diseases caused by 15 serotypes of *Streptococcus pneumoniae*. The vaccine works by conjugating purified capsular polysaccharides from these serotypes to a carrier protein, which enhances the immune response. It is currently being evaluated in healthy Korean adults for its safety and immunogenicity compared to Prevenar13.

Other names: EuBiologics PCV15EuBiologics 15-valent pneumococcal conjugate vaccineEuBiologics15-valent pneumococcal conjugate vaccineEuBiologics-15-valent pneumococcal conjugate vaccinePCV15 (EuBiologics)

Targets

CPS (Streptococcus pneumoniae capsular polysaccharide)

Beyond the preview

Go deeper on EuPCV15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EuPCV15.

Explore the full profile